History Timeline

2016

NEW WEBSITE LAUNCH !

2014

Small scale manufacturing and R&D begins in the DRG Headquarters in USA, managed by several additional staff

2013

Introduction for distribution of the DRG:HYBRiD-XLTM continues through international approval processes with great success Continued development of Elisa kits to utilize with DRG:HYBRiD-XLTM Expanded growth in several international markets including China

2012

New US Headquarters established in Springfield, New Jersey with expanded laboratory space and distribution DRG:HYBRiD-XLTM continues through international approval processes with great success

2011

Introduction of CA 72-4 (FDA Registration now underway)

2010

United States Patent Office issues two more patents to DRG International for development of Hepcidin diagnostic kits DRG International unveils the DRG: HYBRiD-XL® fully-automatic, random access analyzer for immunoassays and clinical chemistry to revolutionize laboratory procedures!

2009

Introduction to market of DRG® Renin, PLGF, Afamin, Anti-Amyloid, Cripto-1, CYR61, L1-Cam, and NOV Elisa kits

2008

United States Patent Office issues two patents to DRG International for development of Hepcidindiagnostic kits

2004

DRG® develops Tumor Markers, CA 72-4, CA 125, CA 15-3, CA 19-9, Cyfra21-1 and introduces Corticosterone andEstrone ELISAs

2003

DRG® develops and introduces the first worldwide Assay for the measurement of Hepcidin DRG® acquires Novum-Diagnostics in Dietzenbach and takes over production of more than 70 ELISAs for Infectious diseases in the DRG-Novum Branch Lab

2002

DRG® develops and introduces various Saliva -and DHEA –ELISAs

2000

DRG® develops and Introduces IGF1, IL-6,Cortisol- Saliva, Androstenedione ELISAs DRG® received certification for QM-System EN ISO9001:1994 DNVon October 27th Dade BehringTechnology is transferred to DRG® production of C5a and PAP – ELISAs

1999

DRG® develops and introduces Insulin, PAPP-A, and TGFßII ELISAs

1998

DRG® moves to a new building in Marburg, Germany DRG Instruments GmbH celebrates 25 years in Marburg, Germany

1997

DRG® develops and introduces Leptin, TGFß,and ß-HCG ELISAs

1996

DRG® develops and introduces Free Estriol ELISA

1995

DRG® develops and Introduces the first worldwide, non-radioactive C-Peptide and Proinsulin Assays

1994

DRG® develops and introduces DHEA-S, Progesterone, Testosterone, PMSG, and βGH ELISAs DRG® opens DRG Diagnostics Branch Office in Berlin, Germany

1993

DRG Techsystemsis founded in Moscow, Russa DRG® develops and introduces 17-OH-Progesterone ELISA

1992

DRG Sp.O.O. is founded in Brno, Czechoslovakia (Czech Rep.) DRG® develops and introduces AFP, HCG, FSH, Prolactin and LH

1991

DRG Biomed founded in St. Petersburg, Russia DRG® launches first neonatal entry of DRG®-ELISA:HPL

1990

DRG MEDTEK founded in Warsaw, Poland DRG® begins R&D and ELISA production in Marburg, Germany

1988

DRG AG founded in Zürich,Switzerland

1985

DRG® begins in-house R&D Operations

1982

DRG® expands in Eastern and Western Europe

1981

DRG® introduces the Mechanical Heart Valve on European Cardiac Surgery Market

1974

DRG Instruments GmbH moves to Marburg, Germany

1973

Distribution of RIA`s in Germany begins DRG Instruments GmbH is founded in Munich, Germany

1970

DRG International, Inc. Is founded by Dr. C.E. Geacintov in New Jersey, USA DRG® enters market in Europe, USSR, Poland and Yugoslavia.

Search Our Products